Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an update.
Shanghai Fosun Pharmaceutical has called its 2026 annual general meeting for 16 June in Shanghai, where shareholders will review the group’s 2025 performance, including the annual report, board work report, profit distribution proposal, and director evaluations and remuneration. The meeting will also vote on reappointing Ernst & Young entities as auditors for 2026 and on a remuneration management system for directors and senior management, signaling continuity in governance and oversight practices.
Shareholders will be asked to approve new and renewed financial mandates, including quotas for entrusted loans, additional credit lines, guarantees, and authorization to dispose of domestic and overseas listed shareholdings held by the group. The board is further seeking a general mandate to issue up to 20% of the existing A and H share capital and related instruments, which would give Fosun Pharma additional flexibility for financing, balance sheet management, and potential strategic transactions in capital markets.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based healthcare and pharmaceutical group listed in Hong Kong that operates across drug manufacturing, medical services, and related health businesses. The company focuses on both domestic and overseas markets, managing a portfolio of listed subsidiaries and investments to support its integrated healthcare strategy.
YTD Price Performance: -2.46%
Average Trading Volume: 2,558,223
Technical Sentiment Signal: Sell
Current Market Cap: HK$71B
For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.